Hope over HIV vaccine

2016-12-01 11:53
Nkosiyazi Mncube (23) is injected as part of the trial of an experimental vaccine at the Verulam HIV Prevention Research Unit on Wednesday morning.

Nkosiyazi Mncube (23) is injected as part of the trial of an experimental vaccine at the Verulam HIV Prevention Research Unit on Wednesday morning. (Abhi Indrarajan)

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories


In absence of vaccine, best prevention of transmission of HIV is treatment - MSF

2015-12-01 13:49

We speak to Dr. Eric Goemaere from Doctors Without Borders, watch him tell us about the progress South Africa has made when it comes to eradicating HIV.WATCH

An HIV/Aids preventative vaccine trial, running only in South Africa, could create immunity to the virus in people. A KwaZulu-Natal research centre’s first trials started on Wednesday.

The trial, called HVTN 702 (HIV Vaccine Trials Network), is the first in the world in seven years, and if effective, could make a major dent in the number of new HIV infections in South Africa.

HVTN and the South African Medical Research Council’s HIV Prevention Research Unit said in a statement that this was the largest and most advanced HIV vaccine clinical trial to take place in the country.

HVTN 702 protocol chair and president and CEO of the Medical Research Council of South Africa (MRC) Professor Glenda Gray said that HIV had taken a “devastating toll” in the country with 1 000 new infections every day. She said the study could hold “great promise”.

“If an HIV vaccine were found to work in South Africa, it could dramatically alter the course of the epidemic.”

The experimental vaccine regimen is based on the one investigated in the RV144 clinical trial in Thailand led by the U.S. Military HIV Research Programme and the Thai Ministry of Health.

The statement said the Thai trial delivered landmark results in 2009, and the experimental vaccine regimen it tested was found to be 31,2% effective in preventing HIV infection over the three-and-a-half-year follow-up period after vaccination.

The HVTN 702 study has been modified to increase the magnitude and duration of the protective immune responses from the vaccine.

HVTN principal investigator Dr Larry Corey said the trial is a “significant” HIV prevention milestone.

“In earlier studies, this vaccine regimen improved on many of the antibody responses to the types of HIV strains circulating in South Africa, providing us the scientific basis to conduct this pivotal trial.

“This study will provide important insights into vaccine development to help prevent new infections and end the epidemic,” he said.

The study is being conducted solely at 15 research centres in South Africa.

The 5 400 study volunteers are being randomly assigned to receive either the investigational vaccine regimen or a placebo.

All study participants will receive injections on five occasions over one year.

The safety of HVTN 702 study participants will be closely monitored throughout the trial.

The vaccines do not contain the whole HIV and therefore do not pose any danger of HIV infection to study participants.

“Despite these precautions, some study participants will become infected with HIV in a similar manner to other members of the community,” said the statement.

“They will be referred to local medical providers for care and treatment and will be counselled on how to reduce their risk of transmitting the virus.”

The trial is being funded by the National Institute for Allergy and Infectious Diseases (NIAID), the Bill & Melinda Gates Foundation, and the South African Medical Research Council (MRC).

If HVTN 702 is shown to be effective, this South African trial could lead to the licensing of the world’s first HIV vaccine.

The KZN site for the trial is in Verulam, Durban.

Verulam HIV Prevention Research Unit principal investigator Dr Anamika Premrajh said they enroled their first female and male volunteers on Wednesday who were “happy and excited” to be part of the trials.

She said the results of the trial should be through by the end of 2020 or the beginning of 2021.

Read more on:    pietermaritzburg

Join the conversation!

24.com encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.

Inside News24

Competition regulation for a growing and inclusive economy

ADVERTORIAL: The Competition Commission of South Africa is conducting advocacy work in the South African automotive aftermarket industry and has gazetted a Draft Code of Conduct for public comment.

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.